Wednesday, July 8, 2026

Patent intelligence · US

US 6077829

Stable pharmaceutical composition of BDNF

expired A61KA61K38/185A61K47/26A61K9/0019
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 837
Patent details — US 6077829
Jurisdiction
US
Status
expired
Grant date
Jun 20, 2000
Expiration
Jun 15, 2020
Claims
17
CPC classes
A61K, A61K38/185, A61K47/26, A61K9/0019
View on Google Patents ↗

Quick answer

US 6077829 (Stable pharmaceutical composition of BDNF) is held by REGENERON PHARMACEUTICALS, INC.. Status: expired. Granted Jun 20, 2000. Expires Jun 15, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K38/185, A61K47/26, A61K9/0019, A61K9/19, A61P

More from REGENERON PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421512

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  2. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  3. US 12421315

    CLL-1 targeted immunotherapies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  4. US 12419963

    Diels-Alder conjugation methods

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 18, 2045

    granted
  5. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 11, 2045

    granted
  6. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    REGENERON PHARMACEUTICALS, INC. · Expires Sep 4, 2045

    granted
  7. US 12404505

    Delivery of a gene-editing system with a single retroviral particle and methods of generation and use

    REGENERON PHARMACEUTICALS, INC. · Expires Aug 28, 2045

    granted
  8. US 12402611

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 6077829?

US 6077829 (Stable pharmaceutical composition of BDNF) is held by REGENERON PHARMACEUTICALS, INC.. Status: expired. Granted Jun 20, 2000. Expires Jun 15, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6077829?

REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.

When does US 6077829 expire?

Our index shows an expiration date of Jun 15, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.